CN111920757B - Purification liquid for treating acarid dermatitis based on synergy of bioactive colloidal sulfur nanoparticles and methionine salt - Google Patents
Purification liquid for treating acarid dermatitis based on synergy of bioactive colloidal sulfur nanoparticles and methionine salt Download PDFInfo
- Publication number
- CN111920757B CN111920757B CN202011006481.9A CN202011006481A CN111920757B CN 111920757 B CN111920757 B CN 111920757B CN 202011006481 A CN202011006481 A CN 202011006481A CN 111920757 B CN111920757 B CN 111920757B
- Authority
- CN
- China
- Prior art keywords
- bioactive
- salicylic acid
- salt
- skin
- allantoin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 title claims abstract description 32
- 230000000975 bioactive effect Effects 0.000 title claims abstract description 22
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 13
- 239000007788 liquid Substances 0.000 title claims abstract description 10
- 238000000746 purification Methods 0.000 title claims description 7
- 239000002105 nanoparticle Substances 0.000 title description 3
- 125000001360 methionine group Chemical class N[C@@H](CCSC)C(=O)* 0.000 title 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 46
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 24
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 23
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical class O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 claims abstract description 14
- LWNZJCOLRQMXHS-UHFFFAOYSA-N 2-acetamido-4-methylsulfanylbutanoic acid;(2,5-dioxoimidazolidin-4-yl)urea Chemical class NC(=O)NC1NC(=O)NC1=O.CSCCC(C(O)=O)NC(C)=O LWNZJCOLRQMXHS-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000004140 cleaning Methods 0.000 claims abstract description 12
- 239000002245 particle Substances 0.000 claims abstract description 12
- 239000000047 product Substances 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 10
- 150000002741 methionine derivatives Chemical class 0.000 claims abstract description 10
- 239000011707 mineral Substances 0.000 claims abstract description 10
- 150000002387 hesperetin Chemical class 0.000 claims abstract description 9
- 241000192132 Leuconostoc Species 0.000 claims abstract description 8
- 241000220259 Raphanus Species 0.000 claims abstract description 8
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims abstract description 8
- 238000000855 fermentation Methods 0.000 claims abstract description 8
- 230000004151 fermentation Effects 0.000 claims abstract description 8
- 239000000706 filtrate Substances 0.000 claims abstract description 8
- 229910017053 inorganic salt Inorganic materials 0.000 claims abstract description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 18
- 239000011593 sulfur Substances 0.000 claims description 18
- 229920001353 Dextrin Polymers 0.000 claims description 10
- 239000004375 Dextrin Substances 0.000 claims description 10
- 235000019425 dextrin Nutrition 0.000 claims description 10
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 9
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 5
- 229960000458 allantoin Drugs 0.000 claims description 5
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 claims description 3
- 239000004927 clay Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 201000004700 rosacea Diseases 0.000 abstract description 19
- 210000001732 sebaceous gland Anatomy 0.000 abstract description 13
- 208000008742 seborrheic dermatitis Diseases 0.000 abstract description 11
- 238000011282 treatment Methods 0.000 abstract description 11
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 abstract description 10
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 206010063409 Acarodermatitis Diseases 0.000 abstract description 5
- 230000002159 abnormal effect Effects 0.000 abstract description 5
- 230000003780 keratinization Effects 0.000 abstract description 5
- 206010017533 Fungal infection Diseases 0.000 abstract description 4
- 208000031888 Mycoses Diseases 0.000 abstract description 4
- 210000003491 skin Anatomy 0.000 description 32
- 230000000694 effects Effects 0.000 description 17
- 206010000496 acne Diseases 0.000 description 16
- 206010015150 Erythema Diseases 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 241001303601 Rosacea Species 0.000 description 13
- 239000011148 porous material Substances 0.000 description 13
- 208000002874 Acne Vulgaris Diseases 0.000 description 12
- 230000028327 secretion Effects 0.000 description 11
- 210000002374 sebum Anatomy 0.000 description 10
- 206010033733 Papule Diseases 0.000 description 8
- 210000000434 stratum corneum Anatomy 0.000 description 8
- 239000013566 allergen Substances 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 208000009056 telangiectasis Diseases 0.000 description 7
- 206010043189 Telangiectasia Diseases 0.000 description 6
- 231100000321 erythema Toxicity 0.000 description 6
- 241001128004 Demodex Species 0.000 description 5
- 206010037888 Rash pustular Diseases 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 238000011010 flushing procedure Methods 0.000 description 5
- 210000004907 gland Anatomy 0.000 description 5
- 210000003780 hair follicle Anatomy 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 208000029561 pustule Diseases 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 241000238876 Acari Species 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 241000220317 Rosa Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 230000002390 hyperplastic effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 210000004373 mandible Anatomy 0.000 description 3
- 229910052901 montmorillonite Inorganic materials 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 2
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 description 2
- 240000009088 Fragaria x ananassa Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- 241000555676 Malassezia Species 0.000 description 2
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 2
- 240000003768 Solanum lycopersicum Species 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000001139 anti-pruritic effect Effects 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 229960001724 brimonidine tartrate Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 2
- 229960001587 hesperetin Drugs 0.000 description 2
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 2
- 235000010209 hesperetin Nutrition 0.000 description 2
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 235000021012 strawberries Nutrition 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 241000307676 Diploprion bifasciatum Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000669298 Pseudaulacaspis pentagona Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- LVPMMWWCJLDZEY-UHFFFAOYSA-N acetyloxysulfonylmethanesulfonic acid Chemical compound CC(=O)OS(=O)(=O)CS(O)(=O)=O LVPMMWWCJLDZEY-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- -1 allantoin methionine salt Chemical class 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000036619 pore blockages Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a cleaning solution for treating acarid dermatitis based on synergy of bioactive colloidal sulfur particles and methionine salt, which comprises the following components by weight: 1-15% of bioactive colloidal sulfur, 1-2% of salicylic acid, 1-5% of plankton extract, 0.1-1.5% of allantoin acetyl methionine salt, 0.1-1% of carboxymethylated hesperetin, 2-10% of modified montmorillonite, 2-5% of glycerol, 2-10% of mineral inorganic salt gel, 2-4% of a filtrate of a fermentation product of leuconostoc/radish root and the balance of water. The purifying liquid can slowly adjust the normal keratinization of the horny layer, recover the abnormal keratinization, stimulate sebaceous glands, control fungal infection and eliminate inflammation aiming at a first-step treatment scheme of seborrheic dermatitis, acarodermatitis and acne rosacea.
Description
Technical Field
The invention relates to the field of skin care products, and in particular relates to a purifying liquid for treating acarodermatitis.
Background
Demodex mites are permanent, small parasitic mites that colonize hair follicles and sebaceous glands of humans and mammals, take up intracellular nutrients and sebaceous gland secretions, thereby destroying normal cells. When the immunity of a human body is reduced, serious skin pathological changes can be caused, such as acarodermatitis, acarodentic acne and the like, and in addition, studies show that demodex has close relationship with seborrheic dermatitis, alopecia and the like appearing on the face of the human body.
Mite dermatitis and seborrheic dermatitis have in common a chronic inflammatory state, which is characterized by: redness and swelling of the skin, excessive telangiectasia, acne-like (papulopustule is a skin appearance), pachynsis, unbalanced flora, overproof malassezia, greasy and hyperplastic skin, dry and tight epidermis, and blocked pores.
Rosacea, also known as rosacea, is a skin disease characterized by redness of the nose, papules, pustules and telangiectasia, which are shaped like strawberries or well-done tomatoes. The skin lesion of the disease is usually rose red and similar to acne, so it is named rose acne. It is commonly seen in adults, and is often seen in people with more facial oil secretion. It is well in the center of the face, especially in the nose and sides, cheeks, glabella and chin, and is usually located at five points, namely the tip, glabella, cheeks, mandible and nasolabial sulcus. The cause of rosacea is also closely related to demodex.
The medicinal use of sulfur began during the period of Hippocrade and continued until now, especially in the treatment of acne. At least 5000 years ago, the ancient egyptian began to treat acne and eczema with sulfur-containing ointments; in the history of Chinese medicine, the history of sulfur in skin care dates back to yellow emperor, which is 2200 years at present. The disease mechanism of demodex is not clear, and the demodex is mainly used as a mite killing agent clinically, such as some sulfur-containing ointments, which have unreasonable formulas, poor pertinence and lack of skin nutrition protection components.
In addition, there are few products for treating the acne rosacea on the skin care product market, and without the step-by-step fine management treatment, one formula can cause the condition to be prolonged without symptomatic treatment or over treatment for all consumers suffering from the acne rosacea. The ophthalmic solution mainly uses azelaic acid and metronidazole gel with larger irritation or brimonidine tartrate eye drops for reducing the pressure of blood vessels to be matched with oral drugs, the time is longer, particularly the brimonidine tartrate eye drops have larger irritation, and the state of consumers is easily influenced by frequently taking anti-inflammatory drugs, such as vestibular imbalance, temporary solution treatment, permanent solution treatment and easy repetition.
Disclosure of Invention
Based on the technical background, the invention aims to provide the cleaning solution for treating the acarid dermatitis based on the synergy of the bioactive colloidal nano sulfur particles and the methionine salt. The first treatment scheme aiming at seborrheic dermatitis, acarodermatitis and acne rosacea can achieve the effects of slowly adjusting normal keratinization of a horny layer, recovering abnormal keratinization, stimulating sebaceous glands, controlling fungal infection and eliminating inflammation.
The invention is realized by the following technical scheme:
a cleaning solution for treating acarid dermatitis based on bioactive colloidal nano sulfur particles and methionine salt, which comprises the following components in parts by weight: 1-15% of bioactive colloidal sulfur, 1-2% of salicylic acid, 1-5% of plankton extract, 0.1-1.5% of allantoin acetyl methionine salt, 0.1-1% of carboxymethylated hesperetin, 2-10% of modified montmorillonite, 2-5% of glycerol, 2-10% of mineral inorganic salt gel, 2-4% of a filtrate of a fermentation product of leuconostoc/radish root and the balance of water.
Further, the dosage of the bioactive colloidal sulfur is preferably 3-12%, and more preferably 5-10%. The bioactive colloidal sulfur plays an important role in maintaining the health of connective tissue, as well as skin, bone, teeth, hair, and muscle. Methionine is involved in the synthesis of many methylated compounds, such as choline, creatine and epinephrine. The sulfur-containing amino acids enter a number of metabolic processes that directly or indirectly control the rate of tissue catabolism, sulfur, as a constituent of cysteine and methionine, is an essential component for protein synthesis in various organisms, replaces lost sulfhydryl groups, contributes to skin metabolism and stimulates epithelialization, preventing skin tissue breakdown. The efficacy of sulfur depends on its direct interaction with the skin. The smaller the particle size, the larger the range of action, and hence the more effective. The therapeutic effect of bioactive colloidal sulfur on skin prone to acne or excessive sebum secretion is attributed to its exfoliating activity. The use of high concentrations of sulfur allows the accumulation of certain amounts of hydrogen sulfide bonds to achieve an exfoliating effect, while the sulfur is converted to pentasulfuric acid on the skin by bacteria and keratinocytes to allow the fungus to be shed from the stratum corneum.
Further, the salicylic acid is dextrin-coated salicylic acid, wherein the content of the salicylic acid is 50%. The dextrin wraps the salicylic acid, and the dosage of the dextrin is preferably 1.2-1.8%. The plankton extract is a microalgae extract, and the dosage of the plankton extract is preferably 2-4%. The salicylic acid and the plankton extract which are cooperatively wrapped are the expression of key mediators for regulating and controlling sebum secretion and inflammation sources, and the effects of inhibiting excessive sebum secretion, relieving redness and inflammation are achieved by reducing the expression of an inflammatory factor C0X-2 participating in sebum secretion, so that pores are cleaned, the mitosis of the skin is reduced to a normal level, and the spreading of pimples and blackheads is prevented. The lipid solubility of salicylic acid can penetrate into the stratum corneum and deep pores and the hair follicle wall by fusing with lipid without causing irritation to the dermal tissue. The hair follicle-stimulating agent can permeate into the deep layer of a pore along a sebaceous gland which secretes grease, can dissolve the constitutional substances among cuticles, is beneficial to dissolving old and accumulated cuticles in the pore, corrects abnormal cell shedding, can help to clear blocked hair follicles, improves the situation of pore blockage, enables the cuticles to shed, can remove the cuticles accumulated thickly, and promotes metabolism.
Further, the allantoin acetylmethionine salt is preferably used in an amount of 0.1 to 1.2%, more preferably 0.1 to 1%. The allantoin acetyl methionine salt is a molecular compound obtained by combining allantoin and acetyl methionine in an equimolar ratio, shows a synergistic effect, and the synergistic effect of combining the allantoin and the acetyl methionine is shown to have high potential in permeating pores, gland pores and various skin pits, and has a beneficial effect on treating common acne and related dermatological diseases. In vitro studies showed that the allantoin acetylmethionine salt had 20 mm and 45 mm efficacy against staphylococcus aureus and propionibacterium acnes, respectively, as measured by the zone of inhibition around the paper discs impregnated with the product. In addition, allantoin acetyl methionate is also helpful for skin metabolism and stimulates epithelization; is helpful for preventing and stopping seborrheic dermatitis; and due to its keratolytic action, it helps in the dissolution of dry scale debris, restoring abnormal keratinization and stimulating sebaceous glands.
Further, the carboxymethylated hesperetin is preferably used in an amount of 0.1 to 0.8%, more preferably 0.3 to 0.5%. Conventional hesperetin is difficult to dissolve in water, and the water solubility of hesperetin is increased after carboxymethylation, so that the effects of protecting and relieving skin pressure, improving the flexibility of blood vessels, repairing capillary walls and maintaining the integrity of the blood vessel walls are achieved. Is beneficial to improving the metabolism and the material exchange capacity of epidermal cell tissues, dredging microcirculation, preventing protein in blood vessels from dissociating out of the blood vessels to cause swelling, resisting edema and exudation, inhibiting the release of inflammatory factors, reducing pimple and improving skin redness.
Further, the amount of the modified montmorillonite is preferably 4 to 8%, more preferably 5 to 7%. The modified montmorillonite is refined inorganic clay salt prepared from natural minerals: the silicate sheets with 700 nm thickness and negatively charged surfaces are stacked by means of electrostatic interaction between layers, and the crystal structure of the silicate sheets has a unique one-dimensional layered structure and high-capacity cation exchange characteristics. The lamellar structure of the skin-care facial mask contains water, the water is gathered by micro scaly particles to form a cabin structure, montmorillonite with the average nano particle size is attached to the surface of the skin by 10 to 20 trillion particles, the protective facial mask is formed by the huge surface area, allergen is intercepted and isolated, the three-dimensional structure of the allergic protein is influenced by positive and negative charges, the allergen can be directionally decomposed by losing the bioactivity of the montmorillonite, and the natural inorganic clay salt has no harm to a human body.
The present invention is directed to a first step treatment regimen for seborrheic dermatitis, acarodermatitis, and rosacea. Colloidal nano octahedral sulfur with strong biological activity is utilized to synergize allantoin methionine salt and montmorillonite with a three-dimensional space structure to form a sulfur-hydrogen bond with skin stratum corneum cells, and when the sulfur-hydrogen bond is accumulated to a certain amount, the death stratum corneum and fungi on the skin can be stripped finally, so that the stratum corneum is normally cornified, and the renewal speed of the stratum corneum is accelerated; meanwhile, the device can help to pull out the hair follicle blocked by sebum secretion secreted by the sebaceous gland, and prevent the sebaceous gland duct and the hair follicle opening from being blocked. In addition, the anti-fungal-infection and anti-allergic agent can also resist fungal infection, condition and inactivate allergens secreted by mites, achieve the effect of inactivating the allergens by destroying the molecular structure of allergenic proteins, neutralize and condition the allergens, resist allergy, relieve itching, relieve redness and inflammation, inhibit sebum oxidation and increase the flexibility of capillary vessels. Has high potential of permeating pores, gland holes and various skin depressions, gently peels off cuticle, is beneficial to dissolving dry scales, and achieves the purposes of inhibiting bacteria and removing mites. Can regulate and control oil secretion, deeply clean pores and has the effect of controlling oil.
Compared with the prior art, the invention can be managed from a plurality of dimensions, and has the following beneficial effects:
1. has high potential of permeating pores, gland pores and various skin depressions, has the function of gently stripping stratum corneum, and is beneficial to dissolving dry scales;
2. has the oil control effect;
3. bacteriostasis, mite removal and allergen neutralization and conditioning;
4. anti-allergic, antipruritic, and anti-redness and inflammation relieving effects, and can inhibit sebum oxidation and increase the flexibility of capillary vessel.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the description of the embodiments are briefly introduced below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings based on these drawings without creative efforts.
FIG. 1 is a comparison graph of a seborrheic dermatitis patient before and after use in one embodiment of the present invention;
FIG. 2 is a comparison of a patient with rosacea before and after use in accordance with another embodiment of the invention;
FIG. 3 is a comparison of a patient with rosacea before and after use in accordance with another embodiment of the invention;
FIG. 4 is a comparison of a patient with rosacea before and after use in accordance with another embodiment of the invention;
FIG. 5 is a comparison of a patient with rosacea before and after use in accordance with another embodiment of the invention;
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
[ first embodiment ] A method for manufacturing a semiconductor device
A cleaning solution for treating acarid dermatitis based on bioactive colloidal nano sulfur particles and methionine salt, which comprises the following components in percentage by weight: 1% of bioactive colloidal sulfur, 1% of dextrin-coated salicylic acid with the salicylic acid content of 50%, 1% of microalgae extract, 1.5% of allantoin acetyl methionine, 1% of carboxymethylated hesperetin, 10% of modified montmorillonite, 3% of glycerol, 7% of mineral inorganic salt gel, 2% of a filtrate of a fermentation product of leuconostoc/radish root and 72.5% of water.
[ second embodiment ]
A cleaning solution for treating acarid dermatitis based on bioactive colloidal nano sulfur particles and methionine salt, which comprises the following components in percentage by weight: 5% of bioactive colloidal sulfur, 1% of dextrin-coated salicylic acid with the salicylic acid content of 50%, 3% of microalgae extract, 0.1% of allantoin acetyl methionine, 0.1% of carboxymethylated hesperetin, 2% of modified montmorillonite, 5% of glycerol, 10% of mineral inorganic salt gel, 4% of a filtrate of a fermentation product of leuconostoc/radish root and 69.8% of water.
[ third embodiment ]
A cleaning solution for treating acarid dermatitis based on bioactive colloidal nano sulfur particles and methionine salt, which comprises the following components in percentage by weight: 15% of bioactive colloidal sulfur, 2% of dextrin-coated salicylic acid with the salicylic acid content of 50%, 5% of microalgae extract, 1% of allantoin acetyl methionine, 0.5% of carboxymethylated hesperetin, 5% of modified montmorillonite, 2% of glycerol, 2% of mineral inorganic salt gel, 2% of a filtrate of a fermentation product of leuconostoc/radish root and 65.5% of water.
[ fourth example ] A
A cleaning solution for treating acarid dermatitis based on bioactive colloidal nano sulfur particles and methionine salt, which comprises the following components in percentage by weight: 12% of bioactive colloidal sulfur, 2% of dextrin-coated salicylic acid with the salicylic acid content of 50%, 2% of microalgae extract, 0.8% of allantoin acetylmethionine, 0.4% of carboxymethylated hesperetin, 9% of modified montmorillonite, 4% of glycerol, 6% of mineral inorganic salt gel, 2% of a filtrate of a fermentation product of leuconostoc/radish root and 61.8% of water.
[ fifth embodiment ]
A cleaning solution for treating acarid dermatitis based on bioactive colloidal nano sulfur particles and methionine salt, which comprises the following components in percentage by weight: 3% of bioactive colloidal sulfur, 1.2% of dextrin-coated salicylic acid with the salicylic acid content of 50%, 4% of microalgae extract, 1.2% of allantoin acetylmethionine, 0.9% of carboxymethylated hesperetin, 3% of modified montmorillonite, 4% of glycerol, 5% of mineral inorganic salt gel, 3% of a Leuconostoc/radish root fermentation product filtrate and 74.7% of water.
Seborrheic dermatitis is a chronic inflammation occurring on the basis of seborrhea, is damaged into bright red or yellowish red patches, is attached with greasy scales or crusts on the surface, and is often accompanied with pruritus of different degrees due to hypersecretion of skin glands, which is manifested by greasy scalp, greasy and shiny, more desquamation and is easy to occur in areas with developed sebum. Patient a is a typical seborrheic dermatitis patient with red and swollen skin, excessive telangiectasia, acne, hypertrophic cutin, unbalanced flora, overproof malassezia, greasy and hyperplastic skin, dry and tight epidermis, and also with skin pruritus according to the patient's dictation. After cleaning the face in the morning and evening, the cleansing liquid prepared in the first embodiment is applied to the affected part, the skin is obviously improved after one week, the red swelling of the skin is subsided, the epidermis is not dry any more, no white scale is seen, and 90% of acnes are treated. FIG. 1 is a graph comparing the effect of patient A before and after treatment with an embodiment of the invention.
Rosacea, also known as rosacea, is a skin disease characterized by redness of the nose, papules, pustules and telangiectasia, which are shaped like strawberries or well-done tomatoes. The skin lesion of the disease is usually rose red and similar to acne, so it is named rose acne. It is well in the center of the face, especially in the nose and sides, cheeks, glabella and chin, and is usually located at five points, namely the tip, glabella, cheeks, mandible and nasolabial sulcus.
Rosacea is clinically generally characterized by three stages, the first stage of erythema: it is manifested as erythema in the middle of the face, especially in the nose, cheeks and mandible, especially after an irritant diet, external temperature changes and mental excitation. Erythema is initially transient and develops into persistent telangiectasias over time, often most pronounced at the tip and lateral alars of the nose. Stage two papulopustular: acne-like papules or pustules appear on the basis of erythema, and the capillaries dilate more obviously and are criss-cross. Third stage nasal wart: in the long term, the nasal connective tissue is hyperplastic, and the sebaceous glands are abnormally enlarged, which results in the swelling of the nasal tip and the formation of nodular bulges of different sizes, called as the nose tag. The surface is uneven, the sebaceous gland orifice is obviously enlarged, white viscous sebum secretion overflows after being squeezed, and the capillary vessel is obviously expanded.
Patient B is a typical erythroid patient, in the early stages of rosacea, exhibiting predominantly flushing facial features. After cleaning the face in the morning and evening, the cleansing liquid prepared in the second example is applied to the affected part, and the affected part is obviously improved after one week, the flushing of the face is eliminated, the secretion of grease is reduced, and the skin is clean and fresh. FIG. 2 is a graph comparing the effect of patient B before and after treatment with an embodiment of the invention.
Patient C is a typical erythema stage patient with telangiectasia and, on erythema basis, a small number of acneiform papules. After cleaning the face in the morning and evening, the cleansing liquid prepared in the third example is applied to the affected part, the affected part is obviously improved after one week, the flushing on the face is relieved, more than 90% of papules are cured, and the capillary vessels are restored to the normal level. Figure 3 is a graph comparing the effect of patient C before and after treatment with an embodiment of the invention.
Patient D was a patient with rosacea at the second stage of papulopustular stage, with marked telangiectasia, criss-cross pattern, large areas of papules and pustules on the skin surface, redness of the face with itching, and clinically severe rosacea. The cleansing liquid prepared in the fourth example was applied to the affected part after cleansing in the morning and evening, and the effect is shown in fig. 4. It can be seen from the figure that the change is obvious every three days, the change is completely improved after two weeks, the papules and pustules on the face are completely cured, pores are fine and smooth, and no scar is seen.
Patient E was the most severe patient with rosacea, in the nose wart stage, with hyperplasia of nasal connective tissue and abnormal enlargement of sebaceous glands, resulting in swollen nasal tip, formation of nodular bumps of varying sizes, uneven nasal surface, significant enlargement of sebaceous glands, extrusion of white viscous sebaceous secretions, and significant dilation of capillaries. In addition, symptoms in the first two stages, flushing of the face, small papules on the cheeks and seborrheic dermatitis were observed. The cleansing liquid prepared in the fourth example was applied to the affected part after cleansing the face in the morning and evening, and two weeks later, the effect was clearly improved. The swelling of the nose tip subsides, the surface is smooth, the capillary vessels shrink to the normal level, the sebaceous glands shrink obviously, the flushing subsides, and the pimple is cured. FIG. 5 is a graph comparing the effect of patient E before and after treatment with an embodiment of the invention.
Therefore, the invention can perform targeted management on the skin from multiple dimensions, has high potential of penetrating into pores, gland holes and various skin depressions, has the function of gently stripping the stratum corneum and is beneficial to dissolving dry scales; has the oil control effect; can inhibit bacteria, remove mites, neutralize and condition allergens; it also has anti-allergic, antipruritic, redness relieving, inflammation relieving, sebum oxidation inhibiting, and capillary flexibility improving effects.
Finally, it should be noted that: the above examples are only intended to illustrate the technical solution of the present invention, but not to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some technical features may be equivalently replaced; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions of the embodiments of the present invention.
Claims (6)
1. The cleaning solution for treating the mite dermatitis based on the synergy of the bioactive colloidal nano sulfur particles and the methionine salt is characterized by comprising the following components in parts by weight: 1-15% of bioactive colloidal sulfur, 1-2% of salicylic acid, 1-5% of plankton extract, 0.1-1.5% of allantoin acetyl methionine salt, 0.1-1% of carboxymethylated hesperetin, 2-10% of modified montmorillonite, 2-5% of glycerol, 2-10% of mineral inorganic salt gel, 2-4% of a filtrate of a fermentation product of leuconostoc/radish root and the balance of water.
2. The purification solution of claim 1, wherein the salicylic acid is a dextrin-coated salicylic acid.
3. The purification solution of claim 2, wherein the dextrin encapsulates salicylic acid, the salicylic acid content being 50%.
4. The purification solution of claim 1, wherein the plankton extract is a microalgae extract.
5. The purification liquid as claimed in claim 1, wherein the allantoin acetylmethionine salt is a molecular complex obtained by combining allantoin and acetylmethionine in an equimolar ratio.
6. The purification solution of claim 1, wherein the modified montmorillonite is a refined inorganic clay salt made from natural minerals.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011006481.9A CN111920757B (en) | 2020-09-23 | 2020-09-23 | Purification liquid for treating acarid dermatitis based on synergy of bioactive colloidal sulfur nanoparticles and methionine salt |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011006481.9A CN111920757B (en) | 2020-09-23 | 2020-09-23 | Purification liquid for treating acarid dermatitis based on synergy of bioactive colloidal sulfur nanoparticles and methionine salt |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111920757A CN111920757A (en) | 2020-11-13 |
CN111920757B true CN111920757B (en) | 2021-05-11 |
Family
ID=73334043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011006481.9A Active CN111920757B (en) | 2020-09-23 | 2020-09-23 | Purification liquid for treating acarid dermatitis based on synergy of bioactive colloidal sulfur nanoparticles and methionine salt |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111920757B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113425666B (en) * | 2021-07-06 | 2023-03-17 | 科丝美诗(中国)化妆品有限公司 | Composition for removing acne and repairing skin barrier as well as preparation method and application thereof |
CN115715754B (en) * | 2022-11-29 | 2025-01-21 | 昆明医科大学 | A gel with acne-removing and repairing effects and preparation thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101317862A (en) * | 2005-11-18 | 2008-12-10 | 赵中州 | Medicament for treating acarodermatitis of human face and preparation method thereof |
WO2009046116A1 (en) * | 2007-10-01 | 2009-04-09 | Dennis Gross | Skin care products containing multiple enhancers |
CN101460060A (en) * | 2006-03-01 | 2009-06-17 | 特莱斯特拉塔公司 | Compositions and methods for topical treatment of tar-responsive skin disorders |
JP2014114290A (en) * | 2013-12-13 | 2014-06-26 | Showa Denko Kk | Cosmetic and skin external preparation |
CN107684530A (en) * | 2017-08-25 | 2018-02-13 | 深圳市雪绒蓝天化妆品贸易有限公司 | Acne-removing composition and preparation method thereof |
CN109528756A (en) * | 2017-09-21 | 2019-03-29 | 扬中牧乐药业有限公司 | A kind of sulfur ointment for treating mink mange and scab |
-
2020
- 2020-09-23 CN CN202011006481.9A patent/CN111920757B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101317862A (en) * | 2005-11-18 | 2008-12-10 | 赵中州 | Medicament for treating acarodermatitis of human face and preparation method thereof |
CN101460060A (en) * | 2006-03-01 | 2009-06-17 | 特莱斯特拉塔公司 | Compositions and methods for topical treatment of tar-responsive skin disorders |
WO2009046116A1 (en) * | 2007-10-01 | 2009-04-09 | Dennis Gross | Skin care products containing multiple enhancers |
JP2014114290A (en) * | 2013-12-13 | 2014-06-26 | Showa Denko Kk | Cosmetic and skin external preparation |
CN107684530A (en) * | 2017-08-25 | 2018-02-13 | 深圳市雪绒蓝天化妆品贸易有限公司 | Acne-removing composition and preparation method thereof |
CN109528756A (en) * | 2017-09-21 | 2019-03-29 | 扬中牧乐药业有限公司 | A kind of sulfur ointment for treating mink mange and scab |
Non-Patent Citations (2)
Title |
---|
ETUDE (爱丽) House Zero Sebum Clearing Powder Toner;无;《http://www.cosdna.com/chs/cosmetic_a994277568.html》;20170314;网页正文 * |
丹姿⽔密码美容液;g;《http://www.cosdna.com/chs/cosmetic_342b37542.html》;20100804;网页正文 * |
Also Published As
Publication number | Publication date |
---|---|
CN111920757A (en) | 2020-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2320362C2 (en) | Proanthocyanidin-containing topical pharmaceutical compositions for treatment of dermatitis | |
KR101420599B1 (en) | Compositions containing anti-acne agents and the use thereof | |
JP6495183B2 (en) | Compositions and methods for treating surface wounds | |
US9962402B2 (en) | Healing composition for topical application | |
WO2006109734A1 (en) | External agent for treating wound | |
CN111920757B (en) | Purification liquid for treating acarid dermatitis based on synergy of bioactive colloidal sulfur nanoparticles and methionine salt | |
US11090205B2 (en) | Methods and compositions for treatment of skin conditions | |
KR100673044B1 (en) | Topical Compositions for Transdermal Administration | |
US9107818B2 (en) | Method of debriding tissue | |
US11045503B2 (en) | Pharmaceutical composition for preventing, treating and curing rosacea, comprising snail slime, chamomile and propolis | |
US10071052B2 (en) | Method for the prevention and treatment of acne | |
US11576926B2 (en) | Composition for use in the prevention and/or treatment of epistaxis | |
EP3348307B1 (en) | Composition comprising carnitine, sodium cholate, sodium acetate and optionally silver for use in the treatment of psoriasis | |
KR20190132197A (en) | Cosmetic composition for use in the treatment and prevention of acne-prone skin | |
EP4085913A1 (en) | Formulation comprising nicotinamide, zinc, copper and glutathione for treating acne rosacea | |
US20240226085A1 (en) | Kynrenine and derivatives thereof for treating atrophic scarring | |
RU2325900C2 (en) | Skin composition of external application | |
TWI325324B (en) | ||
CN119185333A (en) | External medicine for treating acne and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |